Moeckel, Sylvia and Vollmann-Zwerenz, Arabel and Proescholdt, Martin and Brawanski, Alexander and Riemenschneider, Markus J. and Bogdahn, Ulrich and Bosserhoff, Anja-Katrin and Spang, Rainer and Hau, Peter (2016) Validation Study: Response-Predictive Gene Expression Profiling of Glioma Progenitor Cells In Vitro. PLOS ONE, 11 (3): e0151312. ISSN 1932-6203,
Full text not available from this repository. (Request a copy)Abstract
Background In a previous publication we introduced a novel approach to identify genes that hold predictive information about treatment outcome. A linear regression model was fitted by using the least angle regression algorithm (LARS) with the expression profiles of a construction set of 18 glioma progenitor cells enhanced for brain tumor initiating cells (BTIC) before and after in vitro treatment with the tyrosine kinase inhibitor Sunitinib. Profiles from treated progenitor cells allowed predicting therapy-induced impairment of proliferation in vitro. Prediction performance was validated in leave one out cross validation. Methods In this study, we used an additional validation set of 18 serum-free short-term treated in vitro cell cultures to test the predictive properties of the signature in an independent cohort. We assessed proliferation rates together with transcriptome-wide expression profiles after Sunitinib treatment of each individual cell culture, following the methods of the previous publication. Results We confirmed treatment-induced expression changes in our validation set, but our signature failed to predict proliferation inhibition. Neither re-calculation of the combined dataset with all 36 BTIC cultures nor separation of samples into TCGA subclasses did generate a proliferation prediction. Conclusion Although the gene signature published from our construction set exhibited good prediction accuracy in cross validation, we were not able to validate the signature in an independent validation data set. Reasons could be regression to the mean, the moderate numbers of samples, or too low differences in the response to proliferation inhibition in the validation set. At this stage and based on the presented results, we conclude that the signature does not warrant further developmental steps towards clinical application.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | RECURRENT MALIGNANT GLIOMA; CONTINUOUS DAILY SUNITINIB; GLIOBLASTOMA; TRIAL; IDH1; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Hirntumore (ZHT) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 25 Mar 2019 08:13 |
| Last Modified: | 25 Mar 2019 08:13 |
| URI: | https://pred.uni-regensburg.de/id/eprint/3242 |
Actions (login required)
 |
View Item |
